<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518789</url>
  </required_header>
  <id_info>
    <org_study_id>Tangdu-Eto-myo</org_study_id>
    <nct_id>NCT02518789</nct_id>
  </id_info>
  <brief_title>Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus</brief_title>
  <official_title>Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus During General Anesthesia Induction Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tang-Du Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      By observing the difference of plasma homovanillic acid concentrations and brain electrical
      consciousness monitoring Narcotrend index, study the possible mechanism of influencing
      Etomidate induced myoclonus with Dexmedetomidine pretreatment during general anesthesia
      induction period.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>myoclonus level</measure>
    <time_frame>when myoclonus occurs after emulsion injection is completed，assessed up to 5 minutes</time_frame>
    <description>Level 0 ：no myoclonus happened;
Level 1 ：mild, tiny movement, one part of the body such as a finger or shoulder movement;
Level 2 ：moderate ,2 pieces of different muscle or slight movement of the muscle groups, such as face or legs;
Level 3 ：severely, 2 pieces or more muscle contracture intensity, such as fast outreach of limbs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma homovanillic acid concentration（PHVA）</measure>
    <time_frame>Measured when myoclonus occurs after emulsion injection is completed，assessed up to 5 minutes; if myoclonus does not appear,measured at 5 minutes after emulsion injection is completed.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ramsay sedation score</measure>
    <time_frame>1 min after entering the operating room; 1 min after dexmedetomidine injection is completed; 1 min after emulsion injection is completed;5 minutes after emulsion injection is completed；</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotrend index</measure>
    <time_frame>1 min after entering the operating room; 1 min after dexmedetomidine injection is completed; 1 min after emulsion injection is completed;5 minutes after emulsion injection is completed；</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Myoclonus</condition>
  <arm_group>
    <arm_group_label>Low-dose Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 0.5 µg/kg，completed within 15 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 1 µg/kg，completed within 15 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>-Pretreatment before anesthesia induction：Intravenous injection normal saline equal quantity，completed within 15 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose Dexmedetomidine</intervention_name>
    <description>Pretreatment：Intravenous injection dexmedetomidine 0.5 µg/kg ，completed within 15 minutes.</description>
    <arm_group_label>Low-dose Dexmedetomidine</arm_group_label>
    <other_name>Yisi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose dexmedetomidine</intervention_name>
    <description>Pretreatment：Intravenous injection dexmedetomidine 1 µg/kg ，completed within 15 minutes.</description>
    <arm_group_label>High-dose Dexmedetomidine</arm_group_label>
    <other_name>Yisi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Pretreatment：Intravenous injection normal saline equal quantity，completed within 15 minutes.</description>
    <arm_group_label>normal saline Control group</arm_group_label>
    <other_name>Sodium Chloride Physiological Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etomidate</intervention_name>
    <description>After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.
-Does not offer any other drugs within 5 min after completion of etomidate.</description>
    <arm_group_label>Low-dose Dexmedetomidine</arm_group_label>
    <arm_group_label>High-dose Dexmedetomidine</arm_group_label>
    <arm_group_label>normal saline Control group</arm_group_label>
    <other_name>Fuerli</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam，fentanyl，rocuronium</intervention_name>
    <description>Anesthesia induction：Intravenous injection midazolam 0.03 ~ 0.05 mg/kg, fentanyl 5 ~ 8 g/kg, rocuronium 0.6 mg/kg</description>
    <arm_group_label>Low-dose Dexmedetomidine</arm_group_label>
    <arm_group_label>High-dose Dexmedetomidine</arm_group_label>
    <arm_group_label>normal saline Control group</arm_group_label>
    <other_name>Liyuexi，Fentanyl Citrate Injection，Aikesong</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol，remifentanil，cis atracurium</intervention_name>
    <description>Anesthesia maintenance：Intravenous infusion of propofol 4 ~ 6 mg/kg/h, remifentanil 0.1 ~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 ~ 0.1mg/kg</description>
    <arm_group_label>Low-dose Dexmedetomidine</arm_group_label>
    <arm_group_label>High-dose Dexmedetomidine</arm_group_label>
    <arm_group_label>normal saline Control group</arm_group_label>
    <other_name>Propofol Injection，Ruifen，Cisatracurium Besylate Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign the informed consent

          -  American Society of Anesthesiologists (ASA)classification:class I~II;undergoing
             elective surgery patients

          -  Aged between 18 and 55, 49-67 kg weight

          -  Body Mass Index（BMI）： 20-30 kg/m2

          -  Did not use any analgesic or sedatives drugs within 24 h pre-operation

        Exclusion Criteria:

          -  Recently patients undergoing sedative drugs and antidepressant treatment

          -  Serious vision, hearing impairment or other reasons can not communicate

          -  Serious neurological disease, pregnancy, diseases of the cardiovascular system；

          -  BMI is Less than the standard 80% or higher than the standard 120%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LI yumin, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fourth Military Medical University</affiliation>
  </overall_official>
  <reference>
    <citation>Schwarzkopf KR, Hueter L, Simon M, Fritz HG. Midazolam pretreatment reduces etomidate-induced myoclonic movements. Anaesth Intensive Care. 2003 Feb;31(1):18-20.</citation>
    <PMID>12635389</PMID>
  </reference>
  <reference>
    <citation>Stockham RJ, Stanley TH, Pace NL, Gillmor S, Groen F, Hilkens P. Fentanyl pretreatment modifies anaesthetic induction with etomidate. Anaesth Intensive Care. 1988 May;16(2):171-6.</citation>
    <PMID>3394909</PMID>
  </reference>
  <reference>
    <citation>Doenicke AW, Roizen MF, Kugler J, Kroll H, Foss J, Ostwald P. Reducing myoclonus after etomidate. Anesthesiology. 1999 Jan;90(1):113-9.</citation>
    <PMID>9915320</PMID>
  </reference>
  <reference>
    <citation>Paris A, Philipp M, Tonner PH, Steinfath M, Lohse M, Scholz J, Hein L. Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology. 2003 Oct;99(4):889-95.</citation>
    <PMID>14508322</PMID>
  </reference>
  <reference>
    <citation>Maze M, Virtanen R, Daunt D, Banks SJ, Stover EP, Feldman D. Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis: in vivo and in vitro studies. Anesth Analg. 1991 Aug;73(2):204-8.</citation>
    <PMID>1649559</PMID>
  </reference>
  <reference>
    <citation>Venn RM, Bryant A, Hall GM, Grounds RM. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. Br J Anaesth. 2001 May;86(5):650-6.</citation>
    <PMID>11575340</PMID>
  </reference>
  <reference>
    <citation>Mizrak A, Koruk S, Bilgi M, Kocamer B, Erkutlu I, Ganidagli S, Oner U. Pretreatment with dexmedetomidine or thiopental decreases myoclonus after etomidate: a randomized, double-blind controlled trial. J Surg Res. 2010 Mar;159(1):e11-6. doi: 10.1016/j.jss.2009.07.031. Epub 2009 Aug 19.</citation>
    <PMID>20018300</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>August 7, 2015</last_update_submitted>
  <last_update_submitted_qc>August 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myoclonus</keyword>
  <keyword>Etomidate</keyword>
  <keyword>Dexmedetomidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myoclonus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Etomidate</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Atracurium</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Cisatracurium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

